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The congenital dyserythropoietic anemias (CDAs) are inherited red blood cell disorders whose hallmarks are ineffective erythropoiesis,
hemolysis, and morphological abnormalities of erythroblasts in bone marrow. We have identified a missense mutation in KLF1 of
patients with a hitherto unclassified CDA. KLF1 is an erythroid transcription factor, and extensive studies in mouse models have shown
that it plays a critical role in the expression of globin genes, but also in the expression of a wide spectrum of genes potentially essential
for erythropoiesis. The unique features of this CDA confirm the key role of KLF1 during human erythroid differentiation. Furthermore,
we show that themutation has a dominant-negative effect on KLF1 transcriptional activity and unexpectedly abolishes the expression of
the water channel AQP1 and the adhesion molecule CD44. Thus, the study of this disease-causing mutation in KLF1 provides further
insights into the roles of this transcription factor during erythropoiesis in humans.The CDAs represent a heterogeneous group of rare congen-
ital anemias predominantly caused by dyserythropoiesis in
the bone marrow.1 Three major (types I to III) and several
minor subgroups have been differentiated, mainly accord-
ing to the morphological abnormalities of erythroblast
nuclei observed in bone marrow smears (e.g., chromatin
bridges or double nuclei).2,3 The gene responsible for
CDA I (MIM 224120) was identified by positional cloning
in 20024 and coined CDAN1 (MIM 607465), but its func-
tion remains to be elucidated. The gene responsible for
CDA II (MIM 224100) has recently been shown to encode
SEC23B (MIM 610512), which was known to be involved
in the vesicular transport between the endoplasmic retic-
ulum and Golgi apparatus but whose erythroid-specific
role was unsuspected.5,6 Although CDA I and CDA II repre-
sent most cases, the identification of causative genetic
defects in other CDA subgroups or in patients with unclas-
sified CDA may offer further insights into the different
pathways underlying erythropoiesis.
The first CDA patient investigated in this study (male
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The Americansanguineous healthy parents in a context of acute fetal
distress. Hydrops fetalis-associated anemia had been
detected at 23 weeks of gestation and treated with two
intrauterine transfusions; the karyotype of the fetus
was normal. The neonatal examination revealed severe
hyperbilirubinemia, hepatomegaly, hypertrophic cardio-
myopathy, and several dysmorphic features (micropenis,
hypospadia, large anterior fontanel, and hypertelorism).
Anemia did not improve after birth and required transfu-
sions. At 4 months of age, the analysis of bone marrow
smears showed marked hyperplasia of the erythroid
lineage, leading to a diagnosis of CDA, but the dysplastic
changes in the erythroblasts did not clearly fit any classifi-
cation of CDA (Figure S1). Despite treatments with erythro-
poietin or interferon-alpha, thehemolytic anemia persisted
and required recurrent transfusions (at 2–3 week intervals)
until a splenectomy was performed at 4 years of age
(the enlarged spleen showed no pathologic features).
Shortly thereafter, transfusion independencewas achieved,
and hemoglobin levels were stabilized at around 8.0 g/dl
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A Figure 1. Analysis of the Peripheral
Blood of CDA Patient ME Shows Unique
Abnormalities
(A) Peripheral blood smears from the
patient (right panels; sample taken on
10/28/2008) and a control (left panel;
sample taken at the same time) stained
withMay-Gru¨nwaldGiemsa.Note the large
number of circulating erythroblasts (purple
nuclei) as well as poikilocytosis, anisocyto-
sis and fragmented erythrocytes in the
patient. The scale bars represent 40 mm.
(B) Study of the number of enucleated cells
during in vitro erythroid differentiation of
CD34þ cells from the patient (purple;
sample taken on 10/25/2005) or a control
donor (blue). Note the markedly reduced
enucleation capacity of the patient’s cell
culture.
(C) Immunoblot analysis of CD44, CD55,
AQP1, and p55 in erythrocyte membrane
lysates from the patient (CDA; sample
taken on 6/7/2004), his healthy mother
(C2), or a random control (C1). Note the
combined deficiency of CD44 and AQP1
in the patient’s erythrocytes.
(D) Flow-cytometry analysis of CD44 on
mature erythrocytes (left panels) and gran-
ulocytes (right panels) from the patient
(bottom panels; sample taken on 1/5/
2010) and a control (top panels; sample
taken at the same time). Note the
erythroid-specific deficiency of CD44 in
the patient. For the analysis of erythro-
cytes, whole blood samples were costained
with fluorochrome-conjugated anti-CD44
(black histogram) or isotype control anti-
body (white histogram) and anti-CD71,
and the mature erythrocytes were gated
on FSS, SCC, and CD71 so that the retic-
ulocytes and erythroblasts would be elimi-
nated; for the analysis of granulocytes,
nucleated blood cells were first isolated
by hypotonic erythrocyte lysis, then cos-
tained as above and directly gated on FSC
and SSC.
(E) Isoelectric focusing analysis of the different hemoglobin (Hb) variants in the patient (CDA; sample taken on 10/28/2008) and two
controls (C1 and C2). Note the atypical globin expression in the patient; he exhibited very high levels of fetal Hb (a2g2 tetramer,
37.3%; normal range, less that 1%) as well as embryonic Hb Portland (z2g2 tetramer, 2.9%; normal range, absent) as ascertained by
reverse-phase liquid chromatography; adult HbA and HbA2 were at 55.5% (a2b2 tetramer, normal range: 90%–100%) and 1.2% (a2d2
tetramer, normal range: 2%–3%), respectively. Extensive sequencing of patient ME’s globin loci detected no gross abnormalities but
a heterozygous mutation in the a1-globin gene (c.62_63insT, p.His21fsX36), which could not be responsible for the profound b-globin
locus dysregulation and was indeed present in his healthy paternal aunt. Of note, patient SF was a carrier of a 4 bp deletion in the
promoter of Ag-globin gene, as was her healthy father.14
All analyses presented herein were performed on blood samples taken from patient ME after splenectomy and at least 6 months after
transfusion.stature (height 3 SD, weight 2 SD) despite growth-
hormone therapy and treatment for hypothyroidism and
thalassemic facies.
A striking feature of patient ME’s CDA was the very large
number of nucleated red blood cells in his peripheral blood
(there were 210% the number of white blood cells before
splenectomy and up to 1,000% thereafter; Figure 1A and
Table S1). Most of these circulating nucleated red blood
cells were orthochromatic erythroblasts, but only a few
of them were enucleating, which suggested a failure of
terminal erythroid differentiation. Analysis of these cells722 The American Journal of Human Genetics 87, 721–727, Novembby electron microscopy revealed various ultrastructural
abnormalities, especially atypical cytoplasmic inclusions
and enlarged nuclear pores (Figure S2). The in vitro study
of erythroid differentiation of CD34þ cells7 isolated from
patientME’s peripheral blood showed normal proliferation
and differentiation but impaired enucleation capacity
(Figure 1B). Furthermore, when we analyzed a panel of
markers on the surface of his erythrocytes by flow cytome-
try (Figure S3), we noticed the absence of CD44, which
was confirmed by immunoblot analysis (Figure 1C), as
well as reduced expression of two other adhesioner 12, 2010
molecules, BCAM and ICAM4. CD44 was similarly absent
fromhismature erythrocytes and circulating erythroblasts,
but it was present on his granulocytes and all his other
leukocyte populations (Figure 1DandFigure S4), suggesting
thatonly the erythroid lineagewas affected, consistentwith
a CDA trait. We also found that patient ME’s erythrocytes
were deficient in the water channel AQP1 (Figure 1C) and,
consequently, had a reduced water permeability similar to
that of erythrocytes in the very rare AQP1/ individuals8
(Figure S5). Patient ME’s CDA was unique and certainly
different from CDA I and CDA II, as suggested by bone
marrow analysis and later confirmed by the absence of
mutations in CDAN1 and SEC23B (data not shown).
In order to identify the causative genetic defect, we took
fresh blood samples from patient ME and his relatives after
obtaining a signed informed consent under an institu-
tional-review-board-approved protocol, and we extracted
genomic DNA. After unsuccessfully exploring the possi-
bility of an inherited recessive mutation by performing
a SNP-based genome-wide screen in patient ME’s family
(Affymetrix GeneChip Human Mapping 250K Nsp Array,
data not shown), we thought that this unique CDA might
be caused by a de novo mutation in a transcription factor
essential for expression of CD44 (MIM 107269) and
AQP1 (MIM 107776), among others. Because CD44 defi-
ciency was apparently restricted to the erythroid lineage,
we first focused our analysis on erythroid transcription
factors such as GATA1 and KLF1 (also known as
EKLF).9,10 GATA1 represented an attractive candidate,11,12
but no mutations in GATA1 (MIM 305371) were detected
(data not shown). Sequencing of KLF1 (MIM 600599)
(Table S2) in patient ME revealed the presence of two
heterozygous mutations: a T-to-C transition in exon 2
(NM_006563.3:c.304T>C, NP_006554.1:p.Ser102Pro) and
a G-to-A transition in exon 3 (NM_006563.3:c.973G>A,
NP_006554.1:p.Glu325Lys) (Figure S6). A comparison
with the NCBI dbSNP database (build 131) showed that
c.304T>Cmutation corresponded to a previously reported
SNP (rs2072597) and was unlikely to be pathogenic; this
was consistent with rs2072597 heterozygosity of his
healthy mother (data not shown). In contrast, c.973G>A
mutation had never been reported and was not present
in 96 regular blood donors or in patient ME’s relatives
(Figure 2A and data not shown), suggesting it was the
disease-causing mutation.
To verify that the KLF1mutation c.973G>A was respon-
sible for this unique CDA, we searched for it in other
patients. Female patient SF was extensively studied in the
90s, and her atypical CDA showed striking similarities
with that of patient ME: combined deficiency of CD44
and AQP1 on erythrocytes,13 circulating erythroblasts,14
unique ultrastructural abnormalities in erythroblasts,15
and increased electrophoretic mobility of the erythrocyte
membrane protein Band 313 (Figure S7). When we
sequenced KLF1 in patient SF, we found the same heterozy-
gous KLF1 mutation, c.973G>A, as in patient ME (Fig-
ure 2A), verifying that this mutation was responsible forThe Americanthis type of CDA. Of note, and consistent with a de novo
mutation, analysis of KLF1 haplotypes of patients ME and
SF does not support the hypothesis of a founder effect for
the pathogenic KLF1 mutation c.973G>A. In addition to
the previously mentioned unique features of this CDA,
patient SF was shown to express high levels of fetal hemo-
globin, along with embryonic z-globin chain, in the
majority of her erythrocytes.14 When we analyzed patient
ME’s hemoglobin by isoelectric focusing (Figure 1E), we
similarly found large amounts of fetal hemoglobin as well
as an unusual hemoglobin, migrating like embryonic
hemoglobin Portland (z2g2 tetramer), whichwas confirmed
by reverse-phase liquid chromatography (Figure S8). Thus,
the KLF1 mutation c.973G>A was associated with a
profound dysregulation of globin gene expression and
provided in vivo evidence of the critical role of KLF1 in
this complex transcriptional regulation in humans, as pre-
dicted by thalassemia-associatedmutations in the proximal
KLF1 binding sites of b-globin gene16 and extensive studies
in mouse models.17–19 Interestingly, while this manuscript
was being finalized, Borg et al.20 described a large Maltese
family in which a defective KLF1 allele segregates with the
persistence of high levels of fetal hemoglobin in adults—
a benign and usually asymptomatic condition known to
alleviate the severity of b-thalassemia and sickle cell
disease—and they further demonstrated that KLF1 indi-
rectly downregulates fetal globin gene expression by acti-
vating BCL11A expression.
The pathogenic KLF1 mutation c.973G>A results in the
substitution of the evolutionarily conserved glutamate
325 by a lysine (E325K) in the second zinc finger (ZF2) of
KLF1 (Figure 2B). As with arginine 322 and arginine 328,
glutamate 325 is predicted to contact DNA16 (Figure 2C).
In order to investigate the possible structural effect of
the E325K variant, we built a new structural model for the
zinc-finger domain of KLF1 on the basis of the X-ray struc-
tures of Wilms’ tumor protein in complex with DNA.21
The currently used models of KLF1 are based on the struc-
ture of Zif268 bound to DNA,22 but alignment of their
respective zinc-finger domains requires a 2 amino acid gap
inKLF1ZF2,which significantly changes the local topology.
According to the new structural model, glutamate 325 is
located on a helix and is directed toward theDNAbackbone
(Figure 2D, upper left panel). The single amino acid variant
E325K does not alter the overall topology of the KLF1 zinc-
finger domain but mainly affects the side chain of residue
325 (Figure 2D, lower panels). Actually, this charge-reversal
variant enhances the electrostatic interaction between
KLF1and theDNAandpotentially creates anovel hydrogen
bond (Figure 2D, upper right panel). Thus, the E325K
variant is predicted to stabilize, rather than disrupt, the
binding of KLF1 to its DNA target sequences.
Before testing the potential effect of the E325K variant
on KLF1 transcriptional activity, we first wanted to check
whether it affected the stability or cellular localization
of the variant protein. For this purpose, we constructed
vectors encoding either wild-type or E325K variant KLF1Journal of Human Genetics 87, 721–727, November 12, 2010 723
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Figure 2. Identification of the KLF1 Mutation Associated with this CDA and Structural Analysis of the Variant Transcription Factor
(A) A detail of KLF1 sequencing in patient ME, his unaffected mother and sister, and unrelated patient SF show the same heterozygous
KLF1mutation in both CDA patients. The experimental sequences were aligned with the NCBI reference sequence of KLF1 (NG_013087.
1). Genomic DNA samples from patient ME’s father and patient SF’s parents were not available.
(B) A diagram shows the structure of KLF1 (based on NG_013087.1) and its products and highlights the localization of the mutation
c.973G>A, p.Glu325Lys (E325K) was found in patients ME and SF. KLF1 consists of three exons (boxes; black represents coding regions,
and gray represents untranslated regions) and encodes a 362 amino acid peptide with a proline-rich domain at the amino-terminus (the
transactivation domain is in brown) and three C2H2-type zinc fingers (ZF) at the carboxy-terminus (the DNA-binding domain is in
green). The pathogenic mutation is located in the third exon and encodes a single amino acid change in the second zinc finger of
the transcription factor.
(C) A sequence alignment of the second zinc finger of KLF1 from various mammalian species shows the conservation of a glutamate at
amino acid position 325 (red box). The two cysteines and the two histidines contacting Zn2þ are indicated in bold, and the three
conserved residues contacting the DNA are indicated by stars.
(D) Amodeling structure of wild-type (left) and variant E325K (right) zinc-finger domain of KLF1 shows the enhanced electrostatic inter-
action between the E325K variant and the DNA backbone. The change of glutamate to lysine at position 325 exerts a double effect by
reversing the side-chain charge from negative to positive and extending the side-chain length toward the negatively charged DNA
backbone; the putative hydrogen bond created by the E325K variant is shown as a yellow dashed line. The bottom panels show the over-
all structure of the protein-DNA complexes, as well as the electrostatic potential surfaces (negative is in red, positive is in blue) of wild-
type and variant proteins. The top panels show a close-up view of a cartoon representation of the region around residue 325, high-
lighting as sticks the side chain of residue 325 (orange) and the closest nucleotide (light blue); of note, residue 325 is not oriented toward
the nucleotide base but toward the phosphate.tagged with a Flag epitope at the N terminus to allow
its detection and then transfected them into human
erythroid K-562 cells. Flag-tagged KLF1 E325K had the
same expression level as the wild-type protein by immuno-724 The American Journal of Human Genetics 87, 721–727, Novembblot analysis (Figure 3A) and showed the same nuclear
localization by immunofluorescence analysis (Figure 3B).
The combined CD44 and AQP1 deficiencies observed
in this unique CDA suggested that AQP1 and CD44er 12, 2010
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Figure 3. Characterization of the Effect
of the E325K Variant on KLF1 Function
(A) Immunoblot analysis of transfected
K-562 cells shows that the E325K variant
does not affect the stability of KLF1.
Constructs encoding Flag-tagged KLF1
wild-type (WT), variant E325K, or empty
vector were transfected in K-562 cells,
and protein expression was analyzed after
24 hr by immunoblot with anti-Flag and
anti-GAPDH (loading control).
(B) Immunofluorescence analysis of trans-
fected K-562 cells shows that the E325K
variant does not affect the nuclear localiza-
tion of KLF1. K-562 cells transfected as in
(a) were analyzed after 24 hr by immuno-
fluorescence with anti-Flag (green) along
with propidium iodide for DNA staining
(red). No anti-Flag staining was detected
in K-562 cells transfected with the empty
vector (data not shown).
(C) An AQP1 promoter-reporter assay in
K-562 cells shows that the E325K variant
affects the transcriptional activity of
KLF1. K-562 cells were cotransfected with
an AQP1 promoter-Photinus luciferase
(Pluc) construct and a HSV-TK promoter-
Renilla luciferase (Rluc) construct for
normalization, along with 2 mg of the indi-
cated KLF1 constructs, and the luciferase activities were analyzed after 24 hr; the results are shown asmeans5 SD (n¼ 3) of Pluc activity
normalized by Rluc activity.
(D) A CD44 promoter-reporter assay in K-562 cells shows that the E325K variant has a dominant-negative effect on the transcription
activity of KLF1. Not only does KLF1 E325K have a markedly reduced transcriptional activity, but it is also able to impede the transcrip-
tional activity of coexpressed KLF1 wild-type. K-562 cells were cotransfected with a CD44 promoter-Pluc construct and a HSV-TK
promoter-Rluc construct for normalization, along with 2 or 1 mg of the KLF1 constructs as indicated, and the luciferase activities
were analyzed after 24 hr; the results are shown as means5 SD (n ¼ 3) of Pluc activity normalized by Rluc activity.were direct targets of KLF1, which was consistent with the
presence of several potential KLF1 binding sites
(CCNCNCCCN)16 upstream of their respective initiating
codons. Therefore, we studied the effect of the E235K
variant on KLF1 transcriptional activity with CD44 and
AQP1 promoter-reporter assays in K-562 cells. Flag-tagged
KLF1 wild-type was able to activate CD44 and AQP1
promoters, whereas KLF1 E235K showedmarkedly reduced
transcriptional activity (Figures 3C and 3D). Furthermore,
when we coexpressed KLF1 E325K with KLF1 wild-type
in order to mimic heterozygosity of patients ME and SF,
we observed that KLF1 E325K was able to inhibit the acti-
vation of CD44 promoter induced by KLF1 wild-type
(Figure 3D). On the basis of these data, we conclude that
the E325K variant has a dominant-negative effect on the
transcriptional activity of KLF1, in total agreement with
the phenotype of heterozygous patients.
This study describes a missense KLF1 mutation respon-
sible for a human pathology, a hitherto unclassified CDA.
Interestingly, while this manuscript was being finalized,
a new CDA patient with KLF1 mutation c.973G>A was
identified (female patient SE; A.I., unpublished data), sug-
gesting that this type of CDA might be less rare than ex-
pected. The previously reported KLF1 mutations, found
in the heterozygous state too, are responsible for the
blood-group phenotype In(Lu)23 (MIM 111150), which isThe Americanmainly characterized by a reduced expression of Lu (also
known as BCAM) on erythrocytes but which is not associ-
ated with any pathology. Of note, patient SF does not show
a reduced expression of Lu (Figure S9), indicating that the
KLF1 mutation c.973G>A is not directly responsible for
the reduced Lu expression observed in patient ME
(Figure S3). We assume that distinct KLF1mutations might
differently affect the gene repertoire of this transcription
factor and thus lead to different phenotypes, as observed
with GATA1mutations.11,12 Fortuitously, while this manu-
script was being finalized, Siatecka et al.24 reported that
the mouse mutation Nan, a dominant ethylnitrosourea-
induced mutation causing hemolytic anemia, corresponds
to a missense Klf1 mutation encoding the E339D variant
and affecting the expression of only a subset of Klf1 target
genes, and they further showed that the E339D variant
indeed alters Klf1 DNA binding to only a subset of its target
sequences. Of note, glutamate 339 in mouse Klf1 is the
equivalent of glutamate 325 in human KLF1; however,
Klf1 variant E339D is intrinsically different from KLF1
variant E325K because of the opposite charge of the variant
residue (see structure prediction above), which is consis-
tent with the distinct resulting pathologies in mice and
humans. Extensive studies with mouse models suggested
that KLF1 played a global role during erythropoiesis
by regulating a wide spectrum of genes19,25,26 but alsoJournal of Human Genetics 87, 721–727, November 12, 2010 725
organizing nuclear hubs for efficient and coordinated tran-
scription of genes coregulated with the b-globin gene.27,28
This study provides in vivo evidence that human KLF1
plays a critical role in the regulation of fetal globin genes,
as recently demonstrated by Borg et al.20 (see above), but
also of other unexpected genes such as AQP1 and CD44.
Although AQP1 deficiency in humans doesn’t cause dyser-
ythropoiesis,8 we cannot exclude that CD44 deficiency
contributes, even though CD44 is dispensable for mouse
erythropoiesis.29 Future studies will need to identify the
KLF1 target genes whose expression is essential for
human erythropoiesis but that are deficient in this form
of CDA. Finally, we propose that KLF1 should be systemat-
ically sequenced as a novel candidate gene in all CDA cases
with unknown genetic cause; such sequencing might
eventually lead to the discovery of other pathogenic
KLF1 mutations.
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Figure S1. (A) Bone marrow smear from the CDA patient ME before splenectomy (sample taken on 
1997/07/14) showing marked erythroid hyperplasia (77%) with a majority of acidophilic erythroblasts 
(58%). Binucleated erythroblasts (1.0%), multinucleated erythroblasts (1.5%) and few karyorrhexis (star) 
are observed. In some erythroblasts, the cytoplasm contains fine or coarse basophilic stippling of pale 
grayish-blue (arrow). 
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Figure S1. (B) Bone marrow smear from the CDA patient ME after splenectomy (sample taken on 
2001/02/07) showing marked erythroid hyperplasia (80%) with a majority of acidophilic erythroblasts 
(55%). Binucleated erythroblasts (4.5%), multinucleated erythroblasts (2.5%) and few karyorrhexis (star) 
are observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
  
 4 
Figure S2. (A) Transmission electron microscopy of circulating erythroblasts of the CDA patient 
ME showing tubulosaccular inclusions (stars) and elongated cylindrical structures (black arrows) in the 
cytoplasm, and abnormally large nuclear pores (white arrows). Original magnification ×10,000. 
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Figure S2. (B) Transmission electron microscopy of circulating erythroblasts of the CDA patient 
ME showing a wide area of endoreplication of the nuclear membrane. Original magnification ×8,000 (top 
panel) and ×35,000 (bottom panel). 
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Figure S2. (C) Scanning electron microscopy of blood of the CDA patient ME showing severe 
anisopoikilocytosis (top panel, original magnification ×1,930) and small invaginations in erythrocyte 
membrane (stars, bottom panel, original magnification ×4,590). The scale bars represent 10 µm. 
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Figure S3. (A) Flow cytometry analysis of cell markers CD44, CD47, GYPA, BCAM/Lu, ICAM4/LW, 
CD29 and DARC on erythrocytes of the CDA patient ME (right histograms, sample taken on 
2010/01/05) or his healthy mother (left histograms, sample taken at the same time). Erythrocytes were 
stained with mouse monoclonal antibodies (profiles in color) or an isotype control antibody (profile in 
black) and phycoerythrin-conjugated goat F(ab’)2 anti-mouse IgG(H+L), and were gated on FSC and SSC 
(density dot plots). This blood sample from patient ME was taken 4 years after his most recent transfusion, 
and thus was free of exogenous erythrocytes. Patient ME’s erythrocytes abnormally showed no 
expression of CD44, reduced expression of BCAM and ICAM4, and slightly increased expression of 
CD29. Similar results have consistently been observed on samples taken since 2003. 
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Figure S3. (B) Flow cytometry analysis of cell markers CD55, CD58, CD59, CD99, CD151, KEL and 
AChE on erythrocytes of the CDA patient ME (right histograms, sample taken on 2010/01/05) or his 
healthy mother (left histograms, sample taken at the same time). Erythrocytes were stained with mouse 
monoclonal antibodies (profiles in color) or an isotype control antibody (profile in black) and phycoerythrin-
conjugated goat F(ab’)2 anti-mouse IgG(H+L), and were gated on FSC and SSC (density dot plots). This 
blood sample from patient ME was taken 4 years after his most recent transfusion, and thus was free of 
exogenous erythrocytes. The expression of CD99 is highly variable and patient ME’s profile is not 
abnormal. 
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Figure S4. Flow cytometry analysis of CD44 expression in the nucleated cells present in the CDA 
patient ME’s peripheral blood, showing absence of CD44 on his erythroblasts but presence on his 
leukocyte populations. Nucleated blood cells were isolated by hypotonic erythrocyte lysis and triple 
stained with anti-CD44-APC or isotype antibody-APC, anti-CD71-PE and anti-CD45-FITC; granulocytes 
(panel 1) and monocytes (panel 2) were directly gated on FSC and SSC (top left contour plot), while 
lymphocytes (CD71
-
/CD45
+
, panel 3) and erythroblasts (CD71
+
/CD45
-
, panel 4) were further gated on 
CD71 and CD45 expression (bottom left contour plot); the labeling corresponding to anti-CD44-APC 
(colored histograms) or isotype antibody-APC (grey histograms) was analyzed with the same voltage for 
all cell populations. 
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Figure S5. Analysis of the water permeability of the CDA patient ME’s erythrocytes confirming his 
AQP1 deficiency. 
(A) Stopped-flow light scattering measurements of erythrocytes from a control donor (top left panel), an 
AQP1
-/-
 person (also known as Conull blood group phenotype, top right panel), the CDA patient ME (bottom 
right panel) and his healthy mother (bottom left panel) in response to a 150 mOsm inwardly directed 
gradient of mannitol at 15°C; the rapid increase in light scattering results from the shrinkage of 
erythrocytes due to water efflux, allowing to determine their osmotic water permeability. 
(B) Osmotic water permeability coefficients (Pf) of indicated erythrocytes. As the extremely rare AQP1
-/-
 
individuals, patient ME’s erythrocytes showed severely reduced water permeability. Of note, AQP1 is a 
major erythrocyte membrane protein that carries the Colton blood group antigens as well as ABO blood 
group antigens. 
Due to AQP1 deficiency of patient ME’s erythrocytes, their Colton phenotype is expected to be Co(a-b-) 
while blood group genotyping (BioArraySolutions HEA BeadChip Kit) predicts the following extended 
phenotype: C+E–c+e+, K–k+, Kp(a–b+), Js(a–b+), Fy(a+b+), Jk(a+b–), M+N–S–s+, Lu(a–b+), Di(a–b+), 
Co(a+b–), Do(a–b+), Hy+Jo(a+), LW(a+b–), Sc:1,–2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samples ABO type + HgCl2
CDA patient A 0.002485 0.001635
Patient's mother A 0.036400 0.003250
Control A 0.031300 0.003760
Conull (AQP1
-/-
) O 0.004185 0.003930
Controls O 0.030025 0.003441
(n=4)  0.004470 ± 0.000343
Pf  (cm.s
-1
) at 15°C
A
B
Patient’s mother
Control Conull (AQP1
-/-)
time (s)
CDA patient
1,9
2,1
2,3
2,5
2,7
2,9
3,1
0 1 2 3 4
2,0
2,2
2,4
2,6
2,8
3,0
3,2
0 1 2 3 4
1,9
2,1
2,3
2,5
2,7
2,9
3,1
0 1 2 3 4
1,4
1,6
1,8
2,0
2,2
2,4
2,6
0 1 2 3 4
s
c
a
tt
e
re
d
lig
h
t 
in
te
n
s
it
y
(V
)
s
c
a
tt
e
re
d
lig
h
t 
in
te
n
s
it
y
(V
)
  
 11 
Figure S6. (A) Experimental sequence data of KLF1 from the CDA patient ME compared with 
genomic NCBI Reference Sequence NC_000019.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NNN coding sequence 
NNN untranslated sequence 
NNN intronic sequence 
 
GCCGCCTTGCCTTGCTTTGCCTTATCAGAGGCTGCAGCCAATCAGCTAAGGACAGAGAGGAGCCCTCGAAGGGGCTATCACAG
CCTCAGAGTTCACGAGGCAGCCGAGGAAGAGGAGGCTTGAGGCCCAGGGTGGGCACCAGCCAGCCATGGCCACAGCCGAGACC
GCCTTGCCCTCCATCAGCACACTGACCGCCCTGGGCCCCTTCCCGGACACACAGGATGACTTCCTCAAGGTGGGGCCTAGAAG
GTGGGGTCTAGGTGGGCTGGCTGGAATCCAGGGCCACAGTCACAGATCTTGGGGTCCAGACCTGCATCTTGACCTGAAATCAA
GAGACTTAACCAGGACTGAGGTACGCTCAGTCCAGGAGAGGAGATCTCAGCTTAGTCTGGCAGGGGGTGAGGAGGGTGGTCTA
GGGGTTTGAGGTTCTAAGTGTGATCTATTTCGGTAATAGAAAACGAAGGTAGCCTGGGCAACATGGTGAAACCCTATCTCTAC
AAAAAATACCAAAAACATTAGGCCAGGCATGGGGGCGTGTGCCTGTAGTCCCAGGTACTCCGTAGGCTGATGCAGGAGGATCA
TTAGAGCCCAGGAGATTAAGGATACAGTGAGCTGCACCACTGCACTCCAGCCTGGGCAAAAGAGTAAGACCCTATCTCAAGAA
AAAAAAAAAAAAAAAGGAACGAGATCTAGGCTCACAGACAATCTTCCAGATATCAGCGGGAAATGATGAGTGTGTCTGGGGGA
CATCCAAAATTTCGGAATTAATCTTGTTTTGGGAGACAGGGAAGGAGAGGGATGTTCTGGGGGAAAACTAAGTCAAGGCTGGC
ATCCTCTCCCCCGTCCCCTGCCAGTTTTCCATCTCCAGCAGCTCTGCTACCCCTTCCCCCATCCCCGAGTGTGGTTCCAGATA
GTGGAAGTCTTATCTCCTGTCTCCAGCCAGACCTGATCGGTTTCTGTCCCTGGAGCTGGGGGGGGAGCGGGGAGAGGGGCGGT
TAGAGGGGCAGTGTTGGGGAAGTGGGACAGACAGACAGGCAAACAAGACCCCTTTCCAAAGCCTCTGCGTCAGAGTGTCCAGC
CCGCGATGTCCCTGGGCAGGGCACCCCAGTGTCCACCGAACCTCGAGCTGCCTGCTCCCTCCCGCAGTGGTGGCGCTCCGAAG
AGGCGCAGGACATGGGCCCGGGTCCTCCTGACCCCACGGAGCCGCCCCTCCACGTGAAGTCTGAGGACCAGCCCGGGGAGGAA
GAGGACGATGAGAGGGGCGCGGACGCCACCTGGGACCTGGATCTCCTCCTCACCAACTTCTCGGGCCCGGAGCCCGGTGGCGC
GCCCCAGACCTGCGCTCTGGCGCCCAGCGAGGCCYCCGGGGCGCAATATCCGCCGCCGCCCGAGACTCTGGGCGCATATGCTG
GCGGCCCGGGGCTGGTGGCTGGGCTTTTGGGTTCGGAGGATCACTCGGGTTGGGTGCGCCCTGCCCTGCGAGCCCGGGCTCCC
GACGCCTTCGTGGGCCCAGCCCTGGCTCCAGCCCCGGCCCCCGAGCCCAAGGCGCTGGCGCTGCAACCGGTGTACCCGGGGCC
CGGCGCCGGCTCCTCGGGTGGCTACTTCCCGCGGACCGGGCTTTCAGTGCCTGCGGCGTCGGGCGCCCCCTACGGGCTACTGT
CCGGGTACCCCGCGATGTACCCGGCGCCTCAGTACCAAGGGCACTTCCAGCTCTTCCGCGGGCTCCAGGGACCCGCGCCCGGT
CCCGCCACGTCCCCCTCCTTCCTGAGTTGTTTGGGACCCGGGACGGTGGGCACTGGACTCGGGGGGACTGCAGAGGATCCAGG
TGTGATAGCCGAGACCGCGCCATCCAAGCGAGGCCGACGTTCGTGGGCGCGCAAGAGGCAGGCAGCGCACACGTGCGCGCACC
CGGGTTGCGGCAAGAGCTACACCAAGAGCTCCCACCTGAAGGCGCATCTGCGCACGCACACAGGTGAGGGGGCGGGGCCCCGG
ACATGAGAAAGGGCGCGGCGCCCGCTGTAGTTACAGGGGAAGAAGGGTTGCAGAGGGCGGGACTTGGACTTGGCTGGCCTCTG
AGAGTGAGTGCCTCCTTAAATTTTGTGCCCTAGGGGCCTCACTTTGTTCATCCTAGTCCCAGCCCAGGCTGAGTAAAGGGGTG
TGGCCAGATGCAGGGGACCCGGGGACATGACTGGGCAGACAGTGGCGCTTATGGCTTCCTTGTCCCCTAGGGGAGAAGCCATA
CGCCTGCACGTGGGAAGGCTGCGGCTGGAGATTCGCGCGCTCGGACRAGCTGACCCGCCACTACCGGAAACACACGGGGCAGC
GCCCCTTCCGCTGCCAGCTCTGCCCACGTGCTTTTTCGCGCTCTGACCACCTGGCCTTGCACATGAAGCGCCACCTTTGAGCC
CTGCCCTGGCACTTGGACTCTCCTAGTGACTGGGGATGGGACAAGAAGCCTGTTTGGTGGTCTCTTCACACGGACGCGCGTGA
CACAATGCTGGGTGGTTTTCCCACGAATGGACCCTCTCCTGGACTCGCGTTCCCAAAGATCCACCCAAATATCAAACACGGAC
CCATAGACAGCCCTGGGGGAGCCTCTTACGGAAAATCCGACAAGCCTTCAGCCACAGGGAGCCACACAGAGATGTCCAAACTG
TCGTGCAAACCCAGTGAGACAGACCGCCAAATAAACGGACTCAGTGGACACTCAGACCAGCTCCCAGATGGCCCTGGACAGCA
GGAGAGGGTGTGGGATGAGGCTTCCCAGAGACCCTGGGTCTAGAAAGCGGCTCCTGAAGGTCCCTTATTGTGGCTGATATTAA
CTGTCAATGGTTATGGGTCCTATAAAAATGCCCCTCCCAGATAAAGCTTCAGCGTTGGCCTGAATTTTGGGTTTTGGAGGCTG
GAAGATGGCAGGAGGCTGTAAACCTAGAGGTCATATTAGAGGG 
 
Y (heterozygous T/C) for NM_006563.3:c.304T>C, NP_006554.1:p.Ser102Pro (rs2072597) 
R (heterozygous G/A) for NM_006563.3:c.973G>A, NP_006554.1:p.Glu325Lys 
KLF1
19p13
ex1 ex2 ex3
c.973G>A
c.304T>C
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Figure S6. (B) Analysis of heterozygous KLF1 mutation c.973G>A (E325K) from the CDA patient 
ME in both directions with Mutation Surveyor software (SoftGenetics). 
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Figure S7. Analysis of the erythrocyte membrane proteins from the CDA patient ME (CDA, sample 
taken on 2010/01/05) or a control (CTL) showing abnormal migration of Band 3 (arrows) as usually 
observed in CDA II but also slight reduction of spectrins (stars). Proteins were resolved either by 
Laemmli’s (left gel) or Fairbanks’ (right gel) electrophoretic method, and stained with Coomassie Blue. 
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Figure S8. Reverse phase liquid chromatography (RPLC) elution pattern of the hemolysate from 
the CDA patient ME showing the presence of the hydrophobic -globin chain (retention time 84 min). This 
confirmed that the fast migrating hemoglobin observed in isoelectric focusing (IEF) was indeed embryonic 
hemoglobin Portland ( 2 2 tetramer). The peaks and the corresponding retention times of heme, -, 
G
-, 
A
- 
and -globin chains are indicated. 
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Figure S9. Flow cytometry analysis of cell markers CD44, CD47, GYPA, BCAM/Lu, ICAM4/LW, CD29 
and DARC on erythrocytes of the CDA patient SF (right histograms, sample taken on 2009/06/29) or a 
healthy control (left histograms). Erythrocytes were stained with mouse monoclonal antibodies (profiles in 
color) or an isotype control antibody (profile in black) and phycoerythrin-conjugated goat F(ab’)2 anti-
mouse IgG(H+L), and were gated on FSC and SSC (density dot plots). Patient SF’s erythrocytes 
abnormally showed no expression of CD44 and reduced expression of ICAM4; the small CD44
+
 
population (9.5%, star) likely corresponded to the residual erythrocytes of the most recent transfusion 
(2009/04/20) and should be taken into account for the analysis of the other markers, especially ICAM4. 
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Table S1. Essential hematologic parameters of CDA patient ME from birth, before and after 
splenectomy. 
Red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean cellular volume (MCV), mean 
cellular hemoglobin (MCH), mean cellular hemoglobin concentration (MCHC), red-blood-cell distribution 
width (RDW), platelet count (PLT), mean platelet volume (MPV), white blood cell count (WBC). 
Macrocytosis, severe thrombocytosis and extremely high erythroblastosis appeared after splenectomy. 
The three last RBC transfusions were on January 2004 (PT-Hb 7.2 g/dL), February 2005 (PT-Hb 7.2 g/dL) 
and October 2006 (PT-Hb 7.3 g/dL). 
 
 
Date 12/12/1996 14/02/1997 14/03/1997 05/05/1997 16/09/1997 29/01/1998 20/07/1998 20/05/1999 17/08/1999 29/03/2000 03/07/2000 20/04/2001 14/05/2002 25/10/2005 28/10/2008 10/02/2009 05/01/2010
Age 1 day 2 months 3 months 5 months 9 months 1 year 1 year 2 years 2 years 3 years 3 years 4 years 5 years 8 years 11 years 12 years 13 years
(Hospital) (Strasbourg) (Strasbourg) (Strasbourg) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Nancy) (Paris) (Paris) (Nancy) (Nancy) (Nancy) (Nancy)
Parameters Units
RBC 10
12
/L 4,0 2,7 3,8 3,3 2,2 2,7 2,7 2,4 2,7 1,7 1,9 2,5 2,5 2,3 2,7 2,9 2,6
HGB g/dL 11,5 7,5 11,4 9,4 6,5 7,4 7,6 6,7 7,6 4,7 5,4 8,0 8,4 7,5 8,4 9,1 8,0
HCT % 34,1 22,5 33,9 27,9 19,4 21,9 22,8 20,0 23,5 14,2 16,7 26,0 27,0 23,5 27,6 30,1 26,7
MCV fL 86,3 85,0 89,0 83,6 87,7 82,3 84,8 83,8 87,4 85,3 85,9 106,9 108,9 101,0 102,4 102,8 103,4
MCH pg 29,1 28,1 29,9 2,8 29,4 27,8 28,2 28,0 28,2 28,3 27,8 32,2 33,8 32,2 31,1 31,1 31,0
MCHC g/dL 33,7 33,0 33,6 33,7 33,5 33,8 33,3 33,5 32,3 33,1 32,3 30,1 31,0 31,9 30,4 30,2 30,0
RDW % 18,4 16,7 14,6 14,1 14,6 17,5 13,9 20,9 18,2 20,6 24,0
Reticulocytes 10
9
/L 52,5 13,9 62,9 9,0 80,7 134,0 21,5 838 362 422 351 469 304
PLT 10
9
/L 406,0 393,0 229,0 380,0 447,0 339,0 223,0 230,0 211,0 173,0 83,0 526,0 612,0 1020,0 1101,0 1036,0 1264,0
MPV fL 10,4 12,0 10,3 8,9 7,9 8,4 8,6 8,1 8,5 7,8 7,3 10,6 9,3 7,5 9,2 8,1 8,3
WBC 10
9
/L 9,8 20,4 8,2 8,1 13,0 24,2 11,9 15,9 16,0 19,2 27,8 22,7 24,9 15,9 13,9 16,3 16,4
Neutrophils 10
9
/L 3,2 13,5 2,1 1,5 3,7 5,6 3,3 5,6 3,5 11,9 18,6 7,1 7,7 7,8 5,5 9,8 9,2
Eosinophils 10
9
/L 0,4 0,6 0,2 0,3 0,2 0,2 0,1 0,3 0,1 0,2 0,2 1,4 0,8 0,3 0,3 0,3 0,2
Basophils 10
9
/L 0,0 0,0 0,0 0,1 0,2 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,1 0,2 0,0
Lymphocytes 10
9
/L 3,6 3,3 4,8 4,8 7,4 16,5 6,3 8,4 9,8 6,3 7,2 10,9 14,7 6,4 6,1 4,7 4,8
Monocytes 10
9
/L 1,1 2,0 1,2 1,2 1,0 1,9 2,1 1,6 2,6 0,8 1,7 3,4 1,5 1,1 1,8 1,3 1,8
Neutrophils % 33,0 66,0 25,0 18,5 28,4 23,0 28,0 35,0 22,0 62,0 67,0 31,0 34,0 34,3 24,4 42,9 40,5
Eosinophils % 4,0 3,0 2,0 3,8 1,7 1,0 1,0 2,0 0,4 0,8 0,6 6,0 3,3 1,4 1,2 1,5 0,7
Basophils % 0,0 0,0 0,0 0,7 1,4 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,6 0,7 0,0
Lymphocytes % 37,0 16,0 58,0 59,1 56,9 68,0 53,0 53,0 61,0 33,0 26,0 48,0 64,7 28,0 26,8 20,7 20,9
Monocytes % 11,0 10,0 14,0 14,4 7,7 8,0 18,0 10,0 16,0 4,0 6,0 15,0 6,6 4,8 7,9 5,7 8,0
Erythroblasts /100 WBCs 470 12 128 few 12 30 few 100 110 80 210 920 594 1000 1000 500 500
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Table S2. PCR and sequencing primers used to sequence KLF1. 
Location and direction of the primers are based on NCBI KLF1 mRNA Reference Sequence 
NM_006563.3 while position is based on NCBI human chromosome 19 genomic contig NT_011295.11. 
Complete KLF1 was sequenced after PCR amplification of two overlapping fragments using high fidelity 
DNA polymerase as follows. A 5’ KLF1 fragment was amplified by semi-nested PCR with primers KLF1-1, 
KLF1-2 and KLF1-11, and sequenced with primers KLF1-2, KLF1-6 and KLF1-15. A 3’ KLF1 fragment 
was amplified by semi-nested PCR with primers KLF1-7, KLF1-3 and KLF1-4, and sequenced with 
primers KLF1-7, KLF1-8 and KLF1-4. PCR products were sequenced with ABI BigDye terminator 
chemistry (GATC Biotech) after gel purification (Macherey-Nagel). Sequencing data were analyzed with 
DNA Workbench software (CLC bio) and Mutation Surveyor software (SoftGenetics). 
 
 
Name Sequence Location Direction Position
KLF1-1 TAGTCTTTAACCCCAGCCCCAG 5' side of exon 1 Sense 4260969-4260948
KLF1-2 ACGTGAAGTTTGTGCCCCAG 5' side of exon 1 Sense 4260939-4260920

KLF1-3 AGGGGGCTTGTTGGAGTTGAG 3' side of exon 3 Antisense 4257897-4257917
KLF1-4 AGGAGATGAGGGTGTGTAAGG 3' side of exon 3 Antisense 4257935-4257955

KLF1-6 TGATCGGTTTCTGTCCCTGG Intron 1 Sense 4259958-4259939

KLF1-7 AGGATCACTCGGGTTGGGT Exon 2 Sense 4259457-4259439

KLF1-8 TACACCAAGAGCTCCCACC Exon 2 Sense 4258978-4258960
KLF1-11 CGGGTCCCAAACAACTCAG Exon 2 Antisense 4259122-4259140

KLF1-15 GCTTTGGAAAGGGGTCTTG Intron 1 Antisense 4259847-4259865
  
 
 
